Global Nuclear Medicine/Radiopharmaceuticals Market Size By Type (Diagnostic, Therapeutic), By Application (Oncology, Thyroid), By Region, And Segment Forecasts, 2023 to 2032

The Global Nuclear Medicine/Radiopharmaceuticals Market was valued at USD 7.6 billion in 2023 and is projected to surpass USD 16.4 billion by 2031, growing at a CAGR of 9.9% during the forecast period of 2023–2031. The rapid expansion of this market is attributed to the rising prevalence of cancer and cardiovascular diseases, increasing adoption of targeted radionuclide therapy, and significant advancements in imaging technologies. Nuclear medicine enables early and precise diagnosis and personalized treatment through radiopharmaceuticals, playing a transformative role in modern healthcare.

Drivers:

1. Increasing Prevalence of Chronic Diseases:

The global surge in cancer and cardiovascular disorders is a significant driver for nuclear medicine. Radiopharmaceuticals provide a non-invasive and highly accurate method for diagnosing and treating these diseases, thereby fueling market demand.

2. Technological Advancements in Radiotracers and Imaging Modalities:

Continuous innovation in PET and SPECT imaging, coupled with the development of new radioisotopes like Ga-68 and Lu-177, is enhancing the effectiveness of nuclear medicine in both diagnosis and therapy.

3. Growing Adoption of Theranostics:

Theranostics, which combine diagnostics with therapeutics, are becoming increasingly popular. This approach allows for personalized treatment, especially in oncology, where it helps to precisely target and treat tumors.

Restraints:

1. Short Half-Life of Radiopharmaceuticals:

Radiopharmaceuticals have a limited shelf-life, requiring proximity to production facilities or efficient logistics, which limits accessibility in some regions.

2. Regulatory and Reimbursement Challenges:

Stringent regulatory approvals and variable reimbursement policies across countries pose hurdles to widespread adoption and market expansion.

Opportunity:

1. Expansion into Emerging Markets:

Emerging economies, particularly in Asia-Pacific and Latin America, are investing heavily in healthcare infrastructure. This presents a lucrative opportunity for market players to introduce nuclear medicine in underpenetrated regions.

2. Advancements in Targeted Alpha Therapy (TAT):

The rise of alpha-emitting isotopes in cancer therapy is opening new avenues in the treatment of resistant tumors, creating future growth opportunities for developers and suppliers of advanced radiopharmaceuticals.

Market by System Type Insights:

Based on system type, SPECT (Single Photon Emission Computed Tomography) held the largest market share in 2023 due to its affordability and wide diagnostic application range. However, PET (Positron Emission Tomography) is expected to register the highest growth, driven by its superior imaging resolution and increasing use in oncology, neurology, and cardiology.

Market by End-use Insights:

In terms of end use, Hospitals and Diagnostic Centers emerged as the dominant segment in 2023, accounting for over 60% of total revenue. These facilities are primary adopters of nuclear medicine due to their advanced imaging capabilities and high patient throughput. Meanwhile, Research Institutes are anticipated to witness significant growth, fueled by increasing investments in radiopharmaceutical R&D.

Market by Regional Insights:

North America dominated the global market in 2023, attributed to its well-established healthcare infrastructure, advanced research capabilities, and favorable reimbursement environment. However, Asia-Pacific is expected to be the fastest-growing region through 2031, supported by rising healthcare spending, increasing awareness of nuclear medicine applications, and supportive government initiatives in countries like China, India, and South Korea.

Competitive Scenario:

Key players in the global nuclear medicine/radiopharmaceuticals market include GE Healthcare, Siemens Healthineers, Cardinal Health, Lantheus Holdings, Bracco Imaging, Curium, Jubilant Radiopharma, Bayer AG, Telix Pharmaceuticals, and Advanced Accelerator Applications (Novartis). These companies are focusing on expanding their radiopharmaceutical portfolios, obtaining regulatory approvals, and forming strategic partnerships to consolidate their market position.

Scope of Work – Global Nuclear Medicine/Radiopharmaceuticals Market

Report Metric Details

Market Size (2023) USD 7.6 billion

Projected Market Size (2031) USD 16.4 billion

CAGR (2023–2031) 9.9%

Key Segments By System Type (SPECT, PET), By End-use (Hospitals, Diagnostic Centers, Research Institutes), By Region

Growth Drivers Rise in cancer & cardiac disease cases, adoption of theranostics, advancements in imaging technologies

Opportunities Expansion in emerging markets, alpha therapy innovations

Key Market Developments:

2023: Telix Pharmaceuticals received FDA approval for Illuccix, a PSMA PET imaging agent, for prostate cancer diagnosis, enhancing PET imaging accessibility in the U.S.

2024: Curium expanded its radiopharmaceutical production facility in Europe to meet the rising demand for SPECT and PET tracers.

2025: Siemens Healthineers launched a next-gen PET/CT scanner optimized for theranostics, improving diagnostic precision and treatment planning.

FAQs:

1) What is the current market size of the Global Nuclear Medicine/Radiopharmaceuticals Market?

The market was valued at USD 7.6 billion in 2023.

2) What is the major growth driver of the Global Nuclear Medicine/Radiopharmaceuticals Market?

The increasing prevalence of cancer and cardiovascular diseases, along with advancements in imaging technologies, are the major growth drivers.

3) Which is the largest region during the forecast period in the Global Nuclear Medicine/Radiopharmaceuticals Market?

North America holds the largest market share, while Asia-Pacific is projected to grow at the highest rate.

4) Which segment accounted for the largest market share in the Global Nuclear Medicine/Radiopharmaceuticals Market?

The SPECT system type and hospitals/diagnostic centers end-use segments led the market in 2023.

5) Who are the key market players in the Global Nuclear Medicine/Radiopharmaceuticals Market?

Key players include GE Healthcare, Siemens Healthineers, Curium, Cardinal Health, Lantheus, and Bayer AG.

Let me know if you'd like this in a downloadable format or tailored to a specific audience (e.g., investors, academic researchers, or healthcare professionals).